^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Small Cell Lung Cancer
    Drug:Onivyde (nanoliposomal irinotecan) (Topoisomerase I inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Ipsen Press Release
    Title:

    Ipsen receives FDA Fast Track designation for investigational irinotecan liposome injection (ONIVYDE®) as a second-line monotherapy treatment for small cell lung cancer (SCLC)

    Published date:
    11/30/2020
    Excerpt:
    Ipsen today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for irinotecan liposome injection (ONIVYDE) in study patients with small cell lung cancer (SCLC)...